AIMS: The pharmacokinetics and pharmacodynamics of oral dofetilide, a novel, class III antiarrhythmic drug, were assessed during administration either twice or three times daily. METHODS: Dofetilide was administered orally to three groups of healthy subjects in daily doses of 1000 microg (n = 8), 1500 microg (n = 8), or 2500 microg (n = 9) as twice daily and three times daily treatment regimens, with the two regimens assigned randomly as a two-way crossover for each subject and separated by at least a 6 day washout period. RESULTS: Pharmacokinetic analysis indicated a rise in plasma dofetilide concentrations until steady state was attained on day 3. Ctrough had a linear dependence on dose for both the twice daily and three times daily dosing regimens. The maximum concentration attained (Cmax) and the area under the concentration vs time curve (AUC(0,tau) increased linearly with dose for each dosing regimen on both days 1 and 5 of dosing. Cmax occurred at 2 h. Pharmacodynamic measurements showed that the QTc interval increased in a dose-dependent manner and that the time to maximum QTc was 2 h after dosing. A linear relationship was determined between plasma dofetilide concentration and the prolongation of the QTc interval. The slope of this line was significantly greater on day 1 (ranging from 12.9 to 14.2 ms/ng ml-1) than on day 5 (ranging from 9.9 to 12. 8 ms/ng ml(-1). CONCLUSIONS: The pharmacokinetics and pharmacodynamics of dofetilide are predictable and based on a linear relationship for both twice daily and three times daily dosing regimens. The QT responsiveness to dofetilide is greater on day 1 than on day 5.
RCT Entities:
AIMS: The pharmacokinetics and pharmacodynamics of oral dofetilide, a novel, class III antiarrhythmic drug, were assessed during administration either twice or three times daily. METHODS:Dofetilide was administered orally to three groups of healthy subjects in daily doses of 1000 microg (n = 8), 1500 microg (n = 8), or 2500 microg (n = 9) as twice daily and three times daily treatment regimens, with the two regimens assigned randomly as a two-way crossover for each subject and separated by at least a 6 day washout period. RESULTS: Pharmacokinetic analysis indicated a rise in plasma dofetilide concentrations until steady state was attained on day 3. Ctrough had a linear dependence on dose for both the twice daily and three times daily dosing regimens. The maximum concentration attained (Cmax) and the area under the concentration vs time curve (AUC(0,tau) increased linearly with dose for each dosing regimen on both days 1 and 5 of dosing. Cmax occurred at 2 h. Pharmacodynamic measurements showed that the QTc interval increased in a dose-dependent manner and that the time to maximum QTc was 2 h after dosing. A linear relationship was determined between plasma dofetilide concentration and the prolongation of the QTc interval. The slope of this line was significantly greater on day 1 (ranging from 12.9 to 14.2 ms/ng ml-1) than on day 5 (ranging from 9.9 to 12. 8 ms/ng ml(-1). CONCLUSIONS: The pharmacokinetics and pharmacodynamics of dofetilide are predictable and based on a linear relationship for both twice daily and three times daily dosing regimens. The QT responsiveness to dofetilide is greater on day 1 than on day 5.
Authors: D K Walker; G W Aherne; J E Arrowsmith; P E Cross; B Kaye; D A Smith; D A Stopher; W Wild Journal: J Pharm Biomed Anal Date: 1991 Impact factor: 3.935
Authors: Karin Tunblad; Lars Lindbom; Lynn McFadyen; E Niclas Jonsson; Scott Marshall; Mats O Karlsson Journal: J Pharmacokinet Pharmacodyn Date: 2008-11-15 Impact factor: 2.745
Authors: Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro Journal: Drug Saf Date: 2002 Impact factor: 5.606
Authors: T M Haushalter; G S Friedrichs; D L Reynolds; M Barecki-Roach; G Pastino; R Hayes; A S Bass Journal: Br J Pharmacol Date: 2008-07-07 Impact factor: 8.739
Authors: Verena Gotta; Zhiyi Yu; Frank Cools; Karel van Ammel; David J Gallacher; Sandra A G Visser; Frederick Sannajust; Pierre Morissette; Meindert Danhof; Piet H van der Graaf Journal: Pharmacol Res Perspect Date: 2016-11-17
Authors: Zachi I Attia; Alan Sugrue; Samuel J Asirvatham; Michael J Ackerman; Suraj Kapa; Paul A Friedman; Peter A Noseworthy Journal: PLoS One Date: 2018-08-22 Impact factor: 3.240
Authors: Muhammad Erfan Uddin; Eric D Eisenmann; Yang Li; Kevin M Huang; Dominique A Garrison; Zahra Talebi; Alice A Gibson; Yan Jin; Mahesh Nepal; Ingrid M Bonilla; Qiang Fu; Xinxin Sun; Alec Millar; Mikhail Tarasov; Christopher E Jay; Xiaoming Cui; Heidi J Einolf; Ryan M Pelis; Sakima A Smith; Przemysław B Radwański; Douglas H Sweet; Jörg König; Martin F Fromm; Cynthia A Carnes; Shuiying Hu; Alex Sparreboom Journal: Int J Mol Sci Date: 2022-08-03 Impact factor: 6.208